Stifel Nicolaus Raises Elanco Animal Health (NYSE:ELAN) Price Target to $23.00

Key Points

• Stifel Nicolaus has raised the price target for Elanco Animal Health from $18.00 to $23.00, reflecting a potential upside of 22.90% from the stock's current price and maintaining a "buy" rating.
• Elanco's recent quarterly earnings of $0.26 EPS surpassed analysts' expectations, with revenue increasing by 4.8% year-over-year, reaching $1.24 billion.
• Institutional investors hold 97.48% of Elanco's stock, which indicates strong support from hedge funds and investment firms in the company's performance.

Elanco Animal Health (NYSE:ELAN - Get Free Report) had its target price boosted by equities research analysts at Stifel Nicolaus from $18.00 to $23.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' target price suggests a potential upside of 22.90% from the stock's current price.

Several other brokerages have also recently commented on ELAN. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research report on Thursday, July 17th. UBS Group boosted their price target on Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Zacks Research cut Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Finally, Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $18.33.

Elanco Animal Health Price Performance

Shares of ELAN traded up $0.18 during trading hours on Wednesday, hitting $18.72. 1,879,105 shares of the stock were exchanged, compared to its average volume of 5,994,136. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $19.35. The company has a market cap of $9.30 billion, a price-to-earnings ratio of 21.76, a price-to-earnings-growth ratio of 3.53 and a beta of 1.62. The stock's 50-day moving average price is $16.93 and its two-hundred day moving average price is $13.57.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. During the same period in the previous year, the business earned $0.30 earnings per share. The firm's revenue for the quarter was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds have recently bought and sold shares of ELAN. Ameriprise Financial Inc. raised its position in Elanco Animal Health by 127.5% in the 4th quarter. Ameriprise Financial Inc. now owns 97,373 shares of the company's stock valued at $1,179,000 after purchasing an additional 54,581 shares in the last quarter. Cetera Investment Advisers raised its position in shares of Elanco Animal Health by 17.2% during the 4th quarter. Cetera Investment Advisers now owns 31,004 shares of the company's stock worth $375,000 after acquiring an additional 4,553 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of Elanco Animal Health by 1.5% during the 4th quarter. Two Sigma Advisers LP now owns 226,900 shares of the company's stock worth $2,748,000 after acquiring an additional 3,300 shares in the last quarter. Vident Advisory LLC acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth about $122,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Elanco Animal Health by 13.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,716,929 shares of the company's stock worth $20,792,000 after acquiring an additional 206,482 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.